Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will participate in two June 2026 investor conferences. Management joins fireside chats at the Jefferies Global Healthcare Conference on June 3 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 8:00 a.m. ET.
Both fireside chats, along with replays available for 90 days, can be accessed via webcasts in the investor section of ORIC’s website. Management will also hold one-on-one investor meetings at each event.
ORIC (Nasdaq: ORIC) reported Q1 2026 operational updates and cash of $419.7 million as of March 31, 2026. The company selected rinzimetostat 400 mg once daily as the RP3D with darolutamide for the Himalayas-1 Phase 3 in post-abiraterone mCRPC, expected to initiate in 1H 2026.
Rinzimetostat 400 mg showed mostly Grade 1 TRAEs, one Grade 3 TRAE, rare dose modifications, landmark rPFS of 93%, 84%, 84% at 3, 4, 5 months (median follow-up ~4.9 months), and PSA50 in 47% (7/15). Enozertinib Phase 1b enrollment completed for EGFR exon 20 insertion first-line; multiple 2H 2026 clinical updates expected.
ORIC Pharmaceuticals (Nasdaq:ORIC) granted inducement equity on May 1, 2026 to four new non-executive employees: 216,000 non-qualified stock options and 35,000 restricted stock units.
Options carry an exercise price equal to the closing price on May 1, 2026. Vesting: 25% after one year, then monthly 1/36th; RSUs vest one-third on each of the first three anniversaries. Grants were approved under Nasdaq Rule 5635(c)(4) and subject to plan terms and continued service.
ORIC (Nasdaq: ORIC) announced multiple poster presentations at the 2026 AACR Annual Meeting (April 2026) describing preclinical data for rinzimetostat (ORIC-944), an allosteric EED/PRC2 inhibitor for prostate cancer. Key findings: early and sustained PRC2 activity in prostate cancer, combination activity with darolutamide, and activity in PRC2-resistant models.
The posters report rinzimetostat's improved solubility, oral bioavailability, CYP profile, and clinical half-life versus comparators, plus retained activity where EZH1/EZH2 resistance is observed.
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity awards granted on April 1, 2026 to a new non-executive employee hired in March 2026. The company granted 80,000 non-qualified stock options and 15,000 restricted stock units under its 2022 Inducement Equity Incentive Plan, subject to vesting and continued employment.
Options use the closing price on the grant date; options vest 25% after one year then monthly over three years, and RSUs vest one-third annually over three years. Grants were approved by the Compensation Committee as required by Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) selected rinzimetostat 400 mg once daily as the RP3D in combination with darolutamide for the Himalayas-1 global Phase 3 registrational trial, expected to initiate in 1H 2026. Early Phase 1b data (median follow-up ~5 months) show landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, a 47% PSA50 rate (7/15), and 71% achieving >50% ctDNA reduction (10/14). Safety at 400 mg was favorable: mostly Grade 1–2 TRAEs, one Grade 3 TRAE, rare dose modifications. Company plans a ~600-patient, 1:1 randomized Phase 3 with rPFS primary endpoint.
ORIC Pharmaceuticals (Nasdaq: ORIC) will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC).
The company will present results on a conference call and webcast on March 31, 2026 at 4:30pm ET; a replay will be available for 90 days.
ORIC (Nasdaq: ORIC) announced acceptance of multiple preclinical poster presentations on rinzimetostat (ORIC-944) at the AACR Annual Meeting, April 17-22, 2026 in San Diego. Posters (Abstracts 7120, 7132) report preclinical activity of rinzimetostat in PRC2 resistance contexts and combination activity with AR inhibitors in prostate cancer models.
Presentations are scheduled for April 22, 2026, 9:00 a.m.–12:00 p.m. PT in Poster Section 14, Session: Experimental and Molecular Therapeutics.
ORIC Pharmaceuticals (Nasdaq:ORIC) granted inducement equity awards to a new non-executive employee on March 2, 2026. The company awarded 14,800 non-qualified stock options and 2,400 restricted stock units under its 2022 Inducement Equity Incentive Plan.
The stock options carry an exercise price equal to ORIC's closing common stock price on the grant date. Vesting: 25% of options vest after one year, then monthly 1/36th thereafter; RSUs vest one-third on each of the first three anniversaries. Awards were approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) reported Phase 1b data for rinzimetostat in mCRPC and enozertinib in NSCLC, selected provisional RP2Ds, and initiated dose optimization with AR inhibitors. The company raised net proceeds totaling $264 million, reported $392.3M cash and investments (proforma $412.3M) and expects runway into 2H 2028.
ORIC plans multiple 2026 readouts and anticipates a Phase 3 registrational start for rinzimetostat in 1H 2026.